Case series: Symptom‐inhibited fentanyl induction (SIFI) onto treatment‐dose opioid agonist therapy in a community setting
The American Journal on Addictions · 2025-05 · 34 (3) · 355-360
DOI: 10.1111/ajad.70011 ↗Kurz gefasst
Fallbericht in der Zeitschrift The American Journal on Addictions, online erschienen am 18.02.2025. Verfasst von Pouya Azar und 11 weiteren Autor:innen. Beteiligte Einrichtung: Integrated Psychiatry, Pain, and Addiction Service, Vancouver General Hospital, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Analgesics, Opioid, Fentanyl, Opiate Substitution Treatment, Opioid-Related Disorders. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background and Objectives Existing opioid agonist therapy (OAT) guidelines are far from sufficient to address rising opioid tolerances and potency of the unregulated opioid market in North America. Inadequate starting doses of OAT are a universally recognized barrier for people who use fentanyl. Our objectives are to present a novel induction protocol called symptom‐inhibiting fentanyl induction (SIFI) that uses rapid intravenous fentanyl administration to inhibit symptoms of opioid withdrawal.
Methods
We describe two cases highlighting the potential clinical utility of SIFI.
Results
This case series demonstrates two safe and successful transitions onto higher‐than‐standard doses of methadone and slow‐release oral morphine harnessing an emerging approach of SIFI in a community clinic setting. Discussion and Conclusions These results support emerging evidence that SIFI is safe and feasible to meet patients' opioid requirements and facilitate rotation onto OAT. Further studies are needed to increase the generalizability of these findings. Scientific Significance Safe transitions onto treatment‐dose OAT are of heightened clinical importance at a time when fentanyl and high‐potency synthetic opioids are now the norm. SIFI is a novel induction method that could address significant gaps in the currently available OAT options in the fentanyl era.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Integrated Psychiatry, Pain, and Addiction Service, Vancouver General Hospital, Vancouver, British Columbia, Canada.
- Department of Psychiatry, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
- British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
- Substance Use Response and Facilitation Service, BC Children's Hospital, Provincial Health Services Authority, British Columbia, Canada.
- Department of Family Practice, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
- BC Mental Health & Substance Use Services, Provincial Health Services Authority, British Columbia, Canada.
Zitieren
APA
Azar, P., Kim, J. J., Davison, R., Barazanci, Z., Ignaszewski, M. J., Wong, J. S. H., Machado, J., Harris, M., Krausz, M., Mathew, N., Herring, A., & Montaner, J. S. G. (2025). Case series: Symptom‐inhibited fentanyl induction (SIFI) onto treatment‐dose opioid agonist therapy in a community setting. The American Journal on Addictions, 34(3), 355-360. https://doi.org/10.1111/ajad.70011
Vancouver
Azar P, Kim JJ, Davison R, Barazanci Z, Ignaszewski MJ, Wong JSH, et al. Case series: Symptom‐inhibited fentanyl induction (SIFI) onto treatment‐dose opioid agonist therapy in a community setting. The American Journal on Addictions. 2025;34(3):355-360. doi:10.1111/ajad.70011
BibTeX
@article{Azar2025,
author = {Azar, Pouya and Kim, Jane J and Davison, Ruth and Barazanci, Zoran and Ignaszewski, Martha J and Wong, James S H and Machado, Jessica and Harris, Marianne and Krausz, Michael and Mathew, Nickie and Herring, Andrew and Montaner, Julio S G},
title = {Case series: Symptom‐inhibited fentanyl induction (SIFI) onto treatment‐dose opioid agonist therapy in a community setting},
journal = {The American Journal on Addictions},
year = {2025},
volume = {34},
number = {3},
pages = {355--360},
doi = {10.1111/ajad.70011}
}
EUVIMED